Leerink Partnrs Issues Positive Outlook for TNGX Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Leerink Partnrs lifted their Q2 2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.29) for the quarter, up from their previous estimate of ($0.36). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.11) EPS and FY2027 earnings at ($1.80) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The business had revenue of $5.39 million for the quarter, compared to analysts' expectations of $6.73 million.

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $12.33.

Tango Therapeutics Stock Up 8.1%

TNGX traded up $0.19 during midday trading on Thursday, hitting $2.48. 11,256,999 shares of the company traded hands, compared to its average volume of 1,220,263. The company's 50-day moving average is $1.46 and its 200 day moving average is $2.49. The firm has a market capitalization of $268.28 million, a PE ratio of -2.12 and a beta of 1.02. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd bought a new stake in Tango Therapeutics during the fourth quarter valued at approximately $33,000. Stonebrook Private Inc. purchased a new position in shares of Tango Therapeutics during the 4th quarter worth $34,000. Ameriprise Financial Inc. bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at $35,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of Tango Therapeutics in the 4th quarter worth $38,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Tango Therapeutics in the 4th quarter worth $40,000. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.